We are very pleased and encouraged by the FDA’s feedback which clearly defined the regulatory pathway for ST-101 and we are moving quickly forward to submission of the NDA in the United States as well as other regulated countries outside of US” said Pyng Soon, CEO of Stocosil.

Dr. Osmond D’Cruz, Sr. Director of Drug Safety, will be presenting a poster entitled: “Comparative Toxicokinetics and Toxicity of ST-101 (Olmesartan Medoxomil/
Rosuvastatin Calcium) versus Single Agents in Beagle Dogs” at 55th Annual Meeting of the Society of Toxicology, March 13-17, 2016, New Orleans, LA.

Learn More >>